YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Effects of Apigenin, a Flavonoid, on the Bioavailability of Tamoxifen in Rats

흰쥐에서 아피제닌이 타목시펜의 생체이용률에 미치는 영향

  • Received : 2010.06.23
  • Accepted : 2010.09.16
  • Published : 2010.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study is to investigate the effect of apigenin on the pharmacokinetics of tamoxifen in rats. Tamoxifen was administered orally (10 mg/kg) or intravenously (2 mg/kg) without or with oral administration of apigenin (0.4, 2.0 or 8.0 mg/kg) to rats. The effect of apigenin on the P-glycoprotein (P-gp) and CYP3A4 activity was also evaluated. Apigenin inhibited CYP3A4 enzyme activity with 50% inhibition concentration ($IC_{50}$) of 1.8 ${\mu}M$. In addition, apigenin significantly enhanced the cellular accumulation of rhodamine 123 in MCF-7/ADR cells overexpressing P-gp. The plasma concentrations of tamoxifen were increased significantly by apigenin compared to control. The areas under the plasma concentration-time curve (AUC) and the peak concentrations ($IC_{max}$) of tamoxifen with apigenin were significantly higher than those of the control group. Consequently, the relative bioavailability (RB%) of tamoxifen with apigenin was 2-3-fold higher than the control, and absolute bioavailability (AB%) of tamoxifen were significantly higher (p<0.05 with co-administration, p<0.01 with pretreatment) than those of the control. The increased bioavailability of tamoxifen in rats with apigenin might be associated with the inhibition of an efflux pump P-glycoprotein and CYP3A4 by apigenin. From these results, dosage regimen of tamoxifen may be need to adjust when concomitantly administered with apigenin.

Keywords

References

  1. Dixon, R. A. and Steele, C. L. : Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci. 4, 394 (1999). https://doi.org/10.1016/S1360-1385(99)01471-5
  2. Yin, Y., Gong, F. Y., Wu, X. X., Sun, Y., Li, Y. H., Chen, T. and Xu, Q. : Anti-inflammatory and immunosuppressive effect of flavones isolated from Artemisia vestita. J. Ethnopharmacol. 120, 1 (2008). https://doi.org/10.1016/j.jep.2008.07.029
  3. Nafisi, S., Hashemi, M. and Rajabi, M. : DNA Adducts with Antioxidant Flavonoids: Morin, Apigenin, and Naringin. DNA and Cell Biology. 27, 1 (2008). https://doi.org/10.1089/dna.2008.1500
  4. Galati, G., Moridani, M. Y., Chan, T. S. and O'brien, P. J. : Peroxidative metabolism of apigenin and naringenin versus luteolin and quercetin: glutathione oxidation and conjugation. Free Radical Biology & Medicine. 30, 370 (2001). https://doi.org/10.1016/S0891-5849(00)00481-0
  5. Chuang, C. M., Monie, A., Wu, A. and Hung, C. F. : Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J. Biomed. Sci. 16, 49 (2009). https://doi.org/10.1186/1423-0127-16-49
  6. Jeong, G. S., Lee, S. H., Jeong, S. N., Kim, Y. C. and Kim, E. C. : Anti-inflammatory effects of apigenin on nicotine- and lipopolysaccharide-stimulated human periodontal ligament cells via heme oxygenase-1. Int. Immunopharmacol. 9, 1374 (2009). https://doi.org/10.1016/j.intimp.2009.08.015
  7. Gates, M. A., Vitonis, A. F., Tworoger, S. S., Rosner, B., Titus-Ernstoff, L., Hankinson, S. E. and Cramer, D. W. : Flavonoid intake and ovarian cancer risk in a population-based case-control study. Int. J. Cancer. 124, 1918 (2009). https://doi.org/10.1002/ijc.24151
  8. Fukuda, K., Ohta, T., Oshima, Y., Ohashi, N., Yoshikawa, M. and Yamazoe, Y. : Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics. 7, 391 (1997). https://doi.org/10.1097/00008571-199710000-00008
  9. Ho, P. C., Saville, D. J. and Wanwimolruk, S. : Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci. 4, 217 (2001).
  10. Nguyen, H., Zhang, S. and Morris, M. E. : Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci. 92, 250 (2003). https://doi.org/10.1002/jps.10283
  11. Kimura, Y., Ito, H., Ohnishi, R. and Hatano, T. : Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem. Toxicol. 48, 429 (2010). https://doi.org/10.1016/j.fct.2009.10.041
  12. Powles, T. J. : The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 340, 1145 (1992). https://doi.org/10.1016/0140-6736(92)93162-G
  13. Jaiyesimi, I. A., Buzdar, A. U., Decker D. A. and Hortobagyi, G. N. : Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 13, 513 (1995).
  14. Buckley, M. T. and Goa, K. L. : Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin. Pharmacokin. 37, 451 (1989).
  15. Lim, C. K., Yuan, Z. X., Lamb, J. H., White, I. N. H., De Matteis, F. and Smith, L. L. : A comparative study of tamoxifen metabolim in female rat, mouse and human liver microsomes. Carcinogenesis. 15, 589 (1994). https://doi.org/10.1093/carcin/15.4.589
  16. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson A. and Kupfer, D. : Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645 (1993).
  17. Mani, C., Pearce, R., Parkinson, A. and Kupfer, D. : Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 15, 2715 (1994). https://doi.org/10.1093/carcin/15.12.2715
  18. Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier J. C. and Beaune, P. : Involvement of cytochrome P4503A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol. 47, 1883 (1994). https://doi.org/10.1016/0006-2952(94)90319-0
  19. Dehal, S. S. and Kupfer, D. : Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3- hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug. Metab. Dispos. 27, 681 (1999).
  20. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A. and Kupfer, D. : Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450 caralyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645 (1993).
  21. Crewe, H. K., Ellis, S. W., Lennard, M. S. and Tucker, G. T. : Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver mocrosomes. Biochem. Pharmacol. 53, 171 (1997). https://doi.org/10.1016/S0006-2952(96)00650-8
  22. Daniel, P. C., Gaskell, J., Bishop, H., Campbell, C. and Nicholson, R. : Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur. J. Cancer Clin. Oncol. 17, 1183 (1981). https://doi.org/10.1016/S0277-5379(81)80022-3
  23. Jordan, V. C., Collins, M. M., Rowsby, L. and Prestwich, G. : A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305 (1977). https://doi.org/10.1677/joe.0.0750305
  24. Degreforiom, M. W., Coronado, E. and Osborne, C. K. : Tumor and serum tamoxifen concentrations in the athymic nude mice. Cancer Chemother. Pharmacol. 23, 68 (1989). https://doi.org/10.1007/BF00647244
  25. Robinson, S. P., Langan-Fahey, S. M. and Jodan, V. C. : Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur: J. Cancer Clin. Oncol. 25, 1769 (1989). https://doi.org/10.1016/0277-5379(89)90347-7
  26. Gant, T. W., O'Connor, C. K., Corbitt, R., Thorgeirsson, U. and Thorgeirsson, S. S. : In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol. 133, 269 (1995). https://doi.org/10.1006/taap.1995.1151
  27. Rao, U. S., Fine, R. L. and Scarborough, G. A. : Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem. Pharmacol. 48, 287 (1994). https://doi.org/10.1016/0006-2952(94)90099-X
  28. Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993). https://doi.org/10.1146/annurev.bi.62.070193.002125
  29. Gan, L.-S. L., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W. and Thakker, D. R. : CYP3ALike cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996).
  30. Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1996).
  31. Wacher, V. H., Silverman, J. A., Zhng, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidominetics. J. Pharm. Sci. 87, 1322 (1998). https://doi.org/10.1021/js980082d
  32. Fried, K. M. and Wainer, I. W. : Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl. 665, 261 (1994).
  33. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T. : A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 4, 879 (1981). https://doi.org/10.1248/bpb1978.4.879
  34. Reynolds, J. E. F. and Martindale : The Extra Pharmacopeia. Pharmaceutical Press. London (1993).
  35. Yin, Y., Gong, F. Y., Wu, X. X., Sun, Y., Li, Y. H., Chen, T. and Xu, Q. : Anti-inflammatory and immunosuppressive effect of flavones isolated from Artemisia vestita. J. Ethnopharmacol. 120, 1 (2008). https://doi.org/10.1016/j.jep.2008.07.029
  36. Nafisi, S., Hashemi, M. and Rajabi, M. : DNA Adducts with Antioxidant Flavonoids: Morin, Apigenin, and Naringin. DNA and Cell Biology. 27, 1 (2008). https://doi.org/10.1089/dna.2008.1500
  37. Galati, G., Moridani, M. Y., Chan, T. S. and O'brien, P. J. : Peroxidative metabolism of apigenen and naringenin versus luteolin and quercetin : glutathione oxidation and conjugtion. Free Radical Biology & Medicine, 30, 370 (2001). https://doi.org/10.1016/S0891-5849(00)00481-0
  38. Chuang, C. M., Monie, A., Wu, A. and Hung, C. F. : Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J. Biomed. Sci. 27, 49 (2009).
  39. Nguyen, H., Zhang, S. and Morris, M. E. : Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci.92, 250 (2003). https://doi.org/10.1002/jps.10283
  40. Takanaga, H., Ohnishi, A., Matsuo, H. and Sawada, Y. : Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells, Biol. Pharm. Bull. 21, 1062 (1998). https://doi.org/10.1248/bpb.21.1062
  41. Eagling, V. A., Profit, L. and Back, D. J. : Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48, 543 (1999).
  42. Shin, S. C., Choi, J. S. and Lee, X. : Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Inter. J. Pharmaceutics. 313, 144 (2006). https://doi.org/10.1016/j.ijpharm.2006.01.028
  43. Choi, J. S. and Kang, K. W. : Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin. Arch. Pharm. Res. 12, 1631 (2008).